ARTHEx Biotech

All Fund articles Fund PR Portfolio articles Portfolio PR

ARTHEx biotech

ARTHEx Biotech Upsizes Series B Financing Round to $87M

2025.09.172025.12.02 / to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines - Extension financing led by new investor Bpifrance, with renewed participation from al ...

ARTHEx biotech

ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)

2024.10.212025.04.30 / VALENCIA, Spain, Oct. 18, 2024 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expressi ...

ARTHEx biotech

ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

2024.02.282024.05.13 / -ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline to enter the clinic – -First patient expected to be enrolled in Q2 2024- ...

Reaching the next level of creating novel therapies for genetic diseases

2023.05.312024.05.13 / ARTHEx Biotech is entering a new phase in its development of breakthrough treatments for genetically-driven disorders. It’s set to begin the first clinical trials for one of its microRNA modulators a ...

ARTHEx biotech

We are excited to welcome Arthex to our portfolio

2023.05.032024.09.09 / ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1) The ArthemiRTM trial, a Phase I-IIa study of ATX-01 in DM ...